AVROBIO: Clinical Trials

4 terminated, 1 withdrawn. 3 Phase 2, 2 Phase 1, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	3	Terminated 2, Withdrawn 1
Phase 1	2	Terminated 2
Phase 3	1	Withdrawn 1

Follow AVROBIO: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3 Gene therapy, Enzyme Replacement Agent - Gaucher Disease, Type 3	Phase 2 / Phase 3	Withdrawn	AVROBIO		2023-10-01	2023-08-09
A Long-Term Follow-up Study of Subjects With Gaucher Disease Who Previously Received AVR-RD-02 Safety and efficacy assessments - Type 1 Gaucher Disease		Terminated	AVROBIO	4	2021-07-06	2023-08-29
Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease AVR-RD-02 - Gaucher Disease	Phase 1 / Phase 2	Terminated	AVROBIO	8	2019-05-30	2024-01-18
Long-Term Follow-up Study of Subjects With Fabry Disease Who Received Lentiviral Gene Therapy in Study AVRO-RD-01-201 Safety and Efficacy Assessments - Fabry Disease		Terminated	AVROBIO	5	2019-05-08	2023-08-31
Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease AVR-RD-01 - Fabry Disease	Phase 1 / Phase 2	Terminated	AVROBIO	15	2018-02-21	2024-01-05

Conditions studied

Gaucher Disease (3)  ·  Fabry Disease (2)  ·  Lysosomal Storage Diseases (2)

Interventions

Safety (2)  ·  Genetic Therapy (1)  ·  Velaglucerase alfa, human (1)  ·  imiglucerase (1)  ·  taliglucerase alfa (1)

Countries

United States (3)  ·  Australia (2)  ·  Brazil (2)  ·  Canada (2)

Top investigators

Inderpal Panesar, MRPharmS (2)  ·  Milena Veselinovic, MD (2)  ·  Milena Veselinovic, MD, PhD (1)